The B-cell chronic lymphocytic leukemia (CLL)/lymphoma 11B gene (BCL11B) encodes a Kru¨ppel-like zincfinger protein, which plays a crucial role in thymopoiesis and has been associated with hematopoietic malignancies. It was hypothesized that BCL11B may act as a tumorsuppressor gene, but its precise function has not yet been elucidated. Here, we demonstrate that the survival of human T-cell leukemia and lymphoma cell lines is critically dependent on Bcl11b. Suppression of Bcl11b by RNA interference selectively induced apoptosis in transformed T cells whereas normal mature T cells remained unaffected. The apoptosis was effected by simultaneous activation of death receptor-mediated and intrinsic apoptotic pathways, most likely as a result of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) upregulation and suppression of the Bcl-xL antiapoptotic protein. Our data indicate an antiapoptotic function of Bcl11b. The resistance of normal mature T lymphocytes to Bcl11b suppression-induced apoptosis and restricted expression pattern make it an attractive therapeutic target in T-cell malignancies.
Introduction
The B-cell chronic lymphocytic leukemia (CLL)/lymphoma 11B (BCL11B/CTIP2/RIT1/hRita) gene, encodes a Kru¨ppel-like C 2 H 2 zinc-fingers protein that has been initially identified as a transcriptional repressor. It has been shown to mediate its repressor function either directly via binding to a GC-rich consensus sequence (Avram et al., 2002) , or via interacting with chicken ovalbumin upstream promoter-transcription factor nuclear receptors (Avram et al., 2000) , binding with SIRT1 histone deacetylase (HDAC) (Avram et al., 2002; Senawong et al., 2003 Senawong et al., , 2005 and nucleosome remodeling and HDAC complex (NuRD), one of the major transcriptional co-repressor complexes in mammalian cells (Cismasiu et al., 2005; Topark-Ngarm et al., 2006) . Recently, the first evidence has been provided, that Bcl11b activates transcription of the interleukin 2 gene in stimulated CD4
þ T lymphocytes (Cismasiu et al., 2006) . However, the precise function and endogenous transcriptional targets of this transcription factor still remain poorly characterized.
In vivo, BCL11B was shown to be expressed exclusively in the central nervous system and immune system (Leid et al., 2004) . Lack of BCL11B, as shown in germline knockout mice, leads to abnormal thymopoiesis and the complete absence of mature ab T cells (Wakabayashi et al., 2003b) . Specifically, the transition from the double-negative stage 3 (DN3) to DN4 stage was blocked, the rearrangement of T-cell receptor b locus (TRB) was incomplete and extensive apoptosis was observed. Decreased levels of Bcl-xL and Bcl-2 antiapoptotic proteins in sorted DN4 thymocytes obtained from BCL11BÀ/À mice were suggested to contribute to the observed block of thymocyte development (Inoue et al., 2006) .
BCL11B has been also associated with lymphoproliferative disorders. The translocation t(14:14)(q11.2; q32.31) or the inversion inv(14)(q11.2q32.31) disrupting the BCL11B locus were found in one adult T-cell leukemia/lymphoma (ATLL) case and in two cases of Tcell acute lymphoblastic leukemias (T-ALL), respectively (Gesk et al., 2003; Przybylski et al., 2005) . Further translocations involving the BCL11B locus were reported in three T-ALL-derived cell lines and in one case of acute myelocytic leukemia Nagel et al., 2003; Bezrookove et al., 2004) . In mice, deletions within BCL11B were found in normal thymocytes and in irradiation-induced lymphomas (Wakabayashi et al., 2003a; Sakata et al., 2004) . We and others reported high levels of BCL11B mRNA expression in the majority of T-ALL and T-cell leukemia/lymphoma cell lines Przybylski et al., 2005) . Furthermore, BCL11B overexpression was found in the acute type of ATLL in contrast to no or low expression of the gene in the lymphoma type (Oshiro et al., 2006) . Thus, although the mechanisms are not clear, Bcl11b seems to be implicated in the process of oncogenesis.
Here, we report the induction of apoptosis in Jurkat and huT78 human T-cell lymphoma cell lines upon Bcl11b suppression by RNA interference, whereas peripheral blood T cells are not affected. Our findings do not support the hypothesis of BCL11B being a tumor suppressor, but indicate an antiapoptotic activity. Therefore, downregulation of Bcl11b could represent a new therapeutic option in T-cell malignancies.
Results

BCL11B-specific siRNAs suppress BCL11B expression in
Jurkat and huT78 human T-cell leukemia/lymphoma cells To determine the efficiency of BCL11B inhibition after small interfering RNA (siRNA) (BCL11B-674) treatment, BCL11B expression was analysed on the mRNA and protein level. An approximately three to five-fold reduction in mRNA levels was observed 24 h after nucleofection in both cell lines, compared to scrambled non-silencing siRNA (BCL11B-sc) ( Figure 1a) . On the protein level, the Bcl11b knock-down effect reached approximately 80% after 48 h and the suppression persisted 72 h post-transfection ( Figure 1b) . In order to rule out possible off-target effects of the BCL11B-674 duplex, a different Jurkat-tetracycline-inducible BCL11B-RNA interference system was developed. In this system, short hairpin RNA (shRNA-1415), targeting a different BCL11B mRNA region, was expressed from pSuperior-pgk-Neo r -enhanced green fluorescence protein (EGFP) vector after doxycycline induction. Again, Bcl11b protein levels were reduced by 90% upon induction ( Figure 1c ).
BCL11B suppression induces apoptosis in Jurkat and huT78T cell lines
The biological consequences of BCL11B silencing were further studied in T-ALL (Jurkat), T-cell-lymphoma (huT78)-derived cell lines and the BCL11B-negative Raji Burkitt lymphoma cell line as control. The percentage of apoptotic cells was determined by an Annexin-V-fluorescein isothiocyanate (FITC)-binding assay in all three cell lines 48 and 72 h after siRNA treatment. Jurkat and huT78 cells showed a large increase in Annexin-V-positive cells after BCL11B suppression, whereas Raji cells remained unaffected. The effect was detectable 48 h after transfection (not shown), reaching 50 and 80% after 72 h in Jurkat and huT78 cell lines, respectively (Figure 2a ). Control siRNA-treated, untreated or mock-transfected cells showed 5-10% apoptotic cells (not shown). The proapoptotic effect of BCL11B knock down was further confirmed by the determination of the active form of caspase 3 (Figure 2a ) and DNA degradation visualized by staining with propidium iodide (Figure 2a) . Again, BCL11B-siRNA did not influence Raji cells, whereas in Jurkat and huT78, fractions of sub-diploid cells and those of cells positive for active caspase 3 correlated well with Annexin-V-binding measurements.
In the conditional shRNA knock-down system, Jurkat cells showed 60% Annexin-V-positive cells 96 h after induction of BCL11B-specific short hairpin RNA, whereas in the control expressing a non-silencing shRNA species, more than 95% of cells remained viable (Figure 2b ). No significant loss of viability was observed in untreated cells. The caspase 3 activity measured at the same time point was over six times higher in Bcl11b-deficient cells than in controls (Figure 2b ). Even in the absence of the inducer, the caspase 3 activity was slightly increased in cells harboring the functional shRNA vector, most likely as a result of leaky shRNA transcription.
We next examined the dose dependence of BCL11B-siRNA-induced apoptosis in huT78 cells. The percentages of Annexin-positive cells correlated well with the Inhibition of BCL11B leads to apoptosis P Grabarczyk et al amount of BCL11B-674 siRNA used and the BCL11B knock-down efficacy. As expected, no influence on viability was observed in BCL11B-sc treated cells (Figure 2c ). In order to analyse the upstream cascades leading to activation of the effector caspase 3, huT78 cells were treated with specific caspase inhibitors after BCL11B suppression, and apoptosis was measured after 48 and 72 h. The caspase 8-specific inhibitor benzyloxycarbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone (IETD) targeting the major regulatory caspase downstream of the death receptor pathway, reduced the percentage of apoptotic cells by approximately 40% at 48 h and 65% at 72 h (Figure 2d ). The specific caspase 9 inhibitor benzyloxycarbonyl-Leu-Glu(OMe)-His-Asp(OMe)-fluoromethylketone (LEHD), blocking the intrinsic pathway, reduced Annexin-V-positive cells by approximately 30% at both time points. Vehicle as well as a non-blocking peptide Z-FA controls had no effect on viability. This confirmed the involvement of caspases in BCL11B siRNA-induced apoptosis.
BCL11B-siRNA induces TRAIL expression and suppresses BCLxL
To elucidate the molecular mechanisms accounting for BCL11B-siRNA-mediated cell death, global gene expression profiling was performed using the Affymetrix HG U133 Plus 2.0 GeneChip. Jurkat cells were transiently nucleofected with BCL11B-674 and BCL11B-sc siRNAs. Total RNA was isolated 48 h post-transfection, when approximately 80% suppression of Bcl11b protein was detected (Figure 1b ) but ratio of apoptotic to viable cells was low (Figure 2a) . One hundred and ninety-one probe sets were found to be at least twofold regulated upon Bcl11b suppression. A set of 15 genes was measured by quantitative reverse transcription-polymerase chain reaction (QRT-PCR) to assess the accuracy of the array data from which 14 were confirmed (Supplementary data). Two directly apoptosis-related genes were studied in detail: tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and BCLxL.
Array data exhibited fourfold upregulation of the TRAIL mRNA after BCL11B siRNA treatment providing further evidence for the involvement of the Inhibition of BCL11B leads to apoptosis P Grabarczyk et al death-receptor-mediated apoptosis pathway. Further, the antiapoptotic BCLxL gene's levels decreased approximately threefold. For both genes, the microarray data were subsequently verified by TRAIL-and BCLxLspecific QRT-PCR assays in three independent experiments performed with both T-cell lines (Figure 3a and c). The results were confirmed in the tetracyclineinducible knock-down system (not shown). Next, proteins levels of both genes were investigated. Western blot analysis of Bcl-xL in the huT78 cell line revealed significant downregulation of the protein after transient suppression of Bcl11b. Similar results were obtained in Jurkat cells with the conditional shRNAmediated Bcl11b knock-down system ( Figure 3b ).
Cell-surface-bound Trail was measured by fluorescence-activated cell sorting (FACS) analysis in huT78 cells. The percentages of Trail-positive cells correlated very well with the amount of BCL11B-674 duplexes employed (Figure 3d ), the number of apoptotic cells, and with Bcl11b knock-down efficiency ( Figure 2c ).
To assess the individual contribution of Bcl-xL to the pro-apoptotic effects of BCL11B downregulation, a plasmid expression vector encoding Bcl-xL followed by internal ribosome entry site (IRES) and an EGFP Inhibition of BCL11B leads to apoptosis P Grabarczyk et al reporter gene was constructed and co-transfected with BCL11B-specific or control siRNA into Jurkat cells. The 'empty' plasmid containing the IRES-EGFP elements was used as vector control. As shown in Figure 4a , co-transfection of the reporter constructs did not influence the efficiency of Bcl11b suppression, but restored Bcl-xL levels in Bcl11b-deficient cells to baseline. In Bcl11b-deficient cells, apoptosis -quantified in the EGFP-positive sub-population 48 h after treatment was reduced to 10% when the BCLxL vector was applied, compared to over 20% observed in the vector control ( Figure Inhibition of BCL11B leads to apoptosis P Grabarczyk et al
In order to test the contribution of increased TRAIL expression to apoptosis following Bcl11b suppression, we attempted to inactivate the cytokine with Trailneutralizing antibody. First, the neutralizing properties of the antibody were confirmed by simultaneous exposure of huT78 cells to increasing concentrations of human recombinant Trail and 50 ng/ml of the antibody (Figure 5a ). When Bcl11b-deficient huT78 cells were cultured in the presence of the antibody, the fraction of Annexin-V-positive cells dropped dramatically compared to the untreated cells. As expected, the antibody neither influenced TRAIL induction following BCL11B knock down nor reduced the basal rate of apoptosis in cells with normal BCL11B expression (Figure 5b ). The contribution of TRAIL was further analysed by simultaneous double knock down of BCL11B and TRAIL in huT78 cells, abrogating the increase of TRAIL expression, which usually followed BCL11B reduction. As shown in Figure 5c , the reduction of BCL11B mRNA was unaffected by the simultaneous nucleofection of a second siRNA. However, the increase of TRAIL transcription following Bcl11b suppression was abolished and TRAIL mRNA amounts reverted to basal levels upon co-transfection of TRAIL-specific siRNAs. In the latter case, the percentage of apoptotic cells was reduced twofold 48 h after targeting TRAIL in addition to BCL11B (Figure 5d ). TRAIL suppression provided only temporary protection and the effects of TRAIL co-inhibition vanished after 72 h (data not shown).
BCL11B suppression does not induce apoptosis of peripheral blood T lymphocytes
We and others reported, previously, increased BCL11B transcription in acute T-cell leukemia cell lines and primary leukemic T cells in comparison to normal mature T cells. However, Bcl11b protein levels in Jurkat, huT78 and in peripheral blood T cells isolated from three different healthy individuals were similar (Figure 6a ).
To test effects of BCL11B suppression in nontransformed peripheral blood T cells, knock-down experiments were performed. Purified T cells obtained from three healthy individuals were stimulated for proliferation in vitro before transient BCL11B knock down. QRT-PCR and Western blot analysis confirmed the knock-down efficiency (Figure 6b ). Apoptosis measured 72 h after transfection by Annexin-V-binding assay revealed low levels of spontaneous cell death and slight differences between T cells obtained from different donors, but no differences between Bcl11b-deficient and control cells were detected (Figure 6c) . A similar experiment was performed with freshly isolated, purified, non-stimulated and non-proliferating T cells. Once again, no increase of apoptotic cells was seen in Bcl11b-deficient cells (not shown).
These findings prompted us to examine the status of the apoptosis-related genes whose expression was changed after BCL11B knock down in Jurkat and huT78 cells. In the in vitro expanded T lymphocytes, the levels of BCL-xL mRNA and protein were significantly reduced in BCL11B siRNA-treated cells (Figure 7a and b) . TRAIL mRNA was induced significantly in mature T cells but to a lesser extent than in the transformed T-cell lines, not exceeding a twofold upregulation in Bcl11b-deficient cells (Figure 7a ). Although our FACS-based assay did not show any induction of surface-bound Trail following inhibition of BCL11B (Figure 7c ), intracellular Trail measured by enzyme-linked immunosorbent assay (ELISA) was approximately doubled after Bcl11b inhibition compared to control siRNA-treated cells (Figure 7d ). In summary, whereas it reduced Bcl-xL expression and slightly increased Trail, BCL11B knock down did not influence the survival of normal, mature T cells, regardless of their proliferation or activation status.
Mature normal T cells are known to express Bcl-2 antiapoptotic protein. This may substitute for decreased levels of Bcl-xL after BCL11b knock down and make lymphocytes insensitive to Bcl11b suppression. To clarify this issue, we inhibited both genes either alone or simultaneously and showed significant downregulation of Bcl-xL and Bcl-2 expression (Figure 8a ). Apoptosis measured 72 h after treatment confirmed, that downregulation of Bcl-xL via BCL11B knock down does not influence cells' viability. Inhibition of Bcl-2 alone slightly, but significantly decreased cell survival, whereas simultaneous suppression of both genes increased the number of apoptotic cells twofold (Figure 8b) . Treatment of the cells with the apoptosisinducing agent etoposide showed in turn, that only T cells deficient for both antiapoptotic genes were slightly more prone to undergo apoptosis (Figure 8c ). These results support our hypothesis concerning compensatory role of Bcl-2 in BCL11B-deficient normal T lymphocytes, but also indicate, that lack of Bcl11b does not substantially alter their sensitivity to DNA damageinduced cell death.
Discussion
Although much progress has been made in elucidating the mechanisms of BCL11B-mediated transcriptional regulation in vitro and several different potential modes of action have been proposed, the course of events in vivo remains controversial. The lack of BCL11B expression in knockout mice completely blocks the differentiation of ab T lymphocytes (Wakabayashi et al., 2003b) . The authors hypothesized that this could be due to the pronounced sensitivity of thymocytes to apoptotic signals, a lack of pre-T-cell receptor (TCR) signaling, or a functional impairment of parallel pro-survival pathways. These findings emphasize the essential role of BCL11B in thymopoiesis. Most researchers currently favor the idea that BCL11B mainly functions as a tumor-suppressor gene, protecting the cells from uncontrolled cell proliferation and the accompanying massive apoptosis. Support for this hypothesis was +TRAIL Ab -9,7% -TRAIL Ab -78% +TRAIL Ab -30% Figure 5 Role of TRAIL in apoptosis mediated by BCL11B suppression. (a) Neutralization of human recombinant Trail (hrTRAIL) by Trail-neutralizing antibody (TRAIL Ab). Annexin-V-FITC measured 24 h after administration of increasing amounts of soluble recombinant cytokine and 50 ng/ml of Trail Ab. (b) Protective effect of Trail inhibition. HuT78 cells were nucleofetced with BCL11B-674 and sc-siRNA and either left untreated (black lines, ÀTRAIL Ab) or cultured in the presence of 25 ng/ml of Trail-neutralizing antibody ( þ TRAIL Ab). Apoptosis was analysed by Annexin-V-binding assay 72 h after nucleofection. TRAIL mRNA levels measures 48 h after Bcl11b suppression. Membrane bound Trail analysed by FACS 72 h after siRNA transfection. 674, BCL11B-specific siRNA; sc, scrambled control siRNA; Ab, Trail-neutralizing antibody. The illustrated data are representative of three independent experiments. (c) The relative BCL11B and TRAIL mRNA levels analysed 24 h after simultaneous double knock down of both genes in huT78 cells. 674, BCL11B-specific siRNA; sc, scrambled control siRNA; siTRAIL, TRAIL-specific siRNAs; scTRAIL, corresponding scrambled control siRNAs. *Po0.001. (d) Protective effect of TRAIL suppression. Annexin-V measured 48 h after simultaneous double knock down of BCL11B and TRAIL. 674, BCL11B-specific siRNA; sc, scrambled control siRNA; siTRAIL, TRAIL specific siRNAs; scTRAIL, corresponding scrambled control siRNAs. The illustrated data are representative of three independent experiments.
Inhibition of BCL11B leads to apoptosis P Grabarczyk et al provided by the same group, who demonstrated deletions in the BCL11B locus in g-irradiation-induced lymphomas in mice (Wakabayashi et al., 2003a) . The deletions were later found in normal thymocytes and occurred with same frequency in g-irradiated and nonirradiated mice, indicating rather an indirect role of BCL11B mutations in lymphomagenesis (Sakata et al., 2004) Interestingly, the deletions occurred with much higher frequencies in p53-proficient than in p53-deficient lymphomas, which suggested that loss of BCL11B might contribute to oncogenesis only in p53-proficient lymphocytes or was not required any more in p53-null lymphomas. Three possibilities were considered for the relationship between these two proteins: (i) BCL11B functions on the p53-signaling pathway by regulating its expression or being regulated by p53; (ii) BCL11B interacts directly with p53; (iii) both proteins have a similar function but act independently. Whereas the first option is improbable (no changes of BCL11B levels in p53-null mice and p53 expression in BCL11B knockout animals were observed), the latter ones have not been verified yet. Further, contribution of p53 to the effects described here can be excluded, as T-cell lines used are known to carry inactivating p53 mutations.
In keeping with the idea that Bcl11b might act as a tumor suppressor, we recently reported a T-ALL case Inhibition of BCL11B leads to apoptosis P Grabarczyk et al carrying an inversion involving the BCL11B locus, which abolished the expression of the wild-type gene (Przybylski et al., 2005) . However, our data indicate that this is a rare event in T-ALL. In the vast majority of T-ALL cases and T-cell lines, BCL11B is expressed. Taken together, these observations cast some doubt on the tumor-suppressor hypothesis.
To clarify the role of BCL11B in T-cell malignancies, we used RNA interference to inhibit its function in two different human T-cell leukemia and lymphoma-derived cell lines. Our results provide evidence for a major role of BCL11B in promoting the survival of these malignant cells. Moreover, we have at least partially delineated the molecular mechanisms of cell death caused by Bcl11b deficiency.
Two different RNA interference strategies targeting different regions of the BCL11B sequence gave congruent results. Reduction of BCL11B expression resulted in dramatically increased apoptosis in both T-cell leukemia and lymphoma cell lines. This is consistent with the findings of Wakabayashi et al. (2003b) , who detected elevated apoptosis in the thymuses of neonatal BCL11B knockout mice. The pro-apoptotic effect of BCL11B deficiency was pronounced and led to the complete block of thymopoiesis in the early stages in these animals. The analysis of the expression and phosphorylation status of many different apoptosis mediators revealed that only a few of them were involved, among them the antiapoptotic protein BclxL. This observation was confirmed in a recent report by the same group (Inoue et al., 2006) . The authors demonstrated reduced Bcl-xL and Bcl-2 protein levels in sorted DN4 BCL11B (À/À) thymocytes. Interestingly, the transgenic TCRab in those cells reduced apoptosis and raised Bcl-xL and Bcl-2 protein expression without increasing thymus cellularity. These results suggest that Bcl11b influences multiple signaling pathways during thymopoiesis (Inoue et al., 2006) .
Our results confirm in part the latter findings: whereas we did not observe changes in Bcl-2 levels, we showed a marked decrease of Bcl-xL in T-cell lines and in normal mature T cells upon Bcl11b suppression. The restoration of normal Bcl-xL levels in Bcl11b-deficient leukemic cells significantly protected these cells from apoptosis. These observations indicate that Bcl-xL is positively regulated by Bcl11b and that this might contribute to the enhanced survival of transformed T cells. However, the underlying molecular mechanisms by which Bcl11b regulates the expression of Bcl-xL remain to be elucidated.
Our findings are in line with the known role of Bcl-xL in thymopoiesis and malignant transformation. The knockout mouse model showed that, as with Bcl11b, deficiency of Bcl-xL led to massive apoptosis of hematopoietic cells, and impaired maturation and shortened lifespan of lymphocytes (Motoyama et al., 1995) . In turn, overexpression of Bcl-xL within the Tcell lineage resulted in accumulation of thymocytes in lymphoid organs and increased resistance to apoptosis (Grillot et al., 1995) . Moreover, overexpression of BclxL was detected in T-ALL and ATLL cell lines and samples, and its suppression by anti-sense approaches induced apoptosis and sensitized T-ALL cells to chemotherapeutic drugs (Mori et al., 2001; Broome et al., 2002) . Taken together, published data and our findings implicate that Bcl11b and Bcl-xL may act on a common antiapoptotic axis and therefore contribute to malignant transformation in the T-cell lineage.
In addition to Bcl-xL, we found another important apoptosis mediator involved in Bcl11b deficiencyinduced cell death. Transcriptional activation of TRAIL and markedly elevated levels of membrane-bound and intracellular protein have been found in tumor T-cell lines as a result of Bcl11b inhibition. Both the cytokine Trail, which acts via the death-receptor pathway, and agonistic antibodies that bind to its receptors are known to selectively induce apoptosis in various malignant cells, including leukemias. Recently, the upregulation of TRAIL was identified as a molecular basis for the tumor-selective action of HDAC inhibitors in acute myeloid leukemia (Insinga et al., 2005; Nebbioso et al., 2005) . Bcl11b in turn has been found to interact with HDAC1 and HDAC2 within the NuRD nucleosome remodeling complex, and its transcriptional repression activity was abrogated by HDAC inhibitors (Cismasiu et al., 2005) . The authors envisioned that Bcl11b would specifically recruit the NuRD complex to unknown targeted promoters and as a consequence repress gene transcription. This was confirmed recently by detecting the Bcl11b/NuRD complexes on the promoter of p57KIP putative tumor-suppressor gene in neuroblastoma cells (Topark-Ngarm et al., 2006) . Therefore, it is tempting to speculate that TRAIL might be one of the Bcl11b/NuRD target genes, at least in Tcell lineage.
Caspase and neutralization assays indicated that TRAIL might be as important for cell death as Bcl-xL in our system. Although blockade of caspase 9, which is located downstream of Bcl-xL in the intrinsic apoptotic pathway, resulted in only minor increase of viability of Bcl11b-deficient cells, inhibition of caspase 8, acting downstream of TRAIL, markedly reduced the effect of Bcl11b knock down. Similarly, inactivation of TRAIL by neutralizing antibodies or simultaneous knock down also significantly diminished the percentage of apoptotic cells upon Bcl11b suppression in huT78 cells. However, it has been shown that Bcl-xL may be responsible for TRAIL resistance in cancer cells (Sun et al., 2002; Kim et al., 2003; Zhang and Fang, 2005a) and that Bcl-xL suppression is required for TRAIL-mediated apoptosis in different experimental systems (Bradham et al., 1998; Medema et al., 1998) . Therefore, Bcl-xL and TRAIL probably act in concert through a crosstalk between the intrinsic and death receptor-mediated pathways of apoptosis.
It is known that Bcl11b is required for differentiation and survival of ab thymocytes. Our results show that survival of transformed T-cell lines in vitro is dramatically decreased upon Bcl11b suppression. Therefore, we next investigated the consequences of Bcl11b inhibition in normal, mature T cells. First, we showed that elevated BCL11B mRNA levels in T-cell lines and leukemia samples did not correspond with increased protein levels. Obviously, transcription and translation are regulated differently in normal and malignant T cells. Interestingly, we did not observe any decrease in viability or increased sensitivity to DNA damageinduced apoptosis of in vitro cultured Bcl11b-deficient peripheral blood T cells. Although a marked downregulation of Bcl-xL was observed, TRAIL mRNA was elevated marginally compared to the transformed T-cell lines, and Trail protein could not be detected on the cell surface upon Bcl11b inhibition. However, intracellular Trail increased slightly but significantly, which is in line with findings, that normal T cells upon stimulation secrete Trail rather than retain it on their surface (Ehrlich et al., 2003) .
It has been reported that, in contrast to thymocytes and transformed T cells, normal mature T cells may be independent of Bcl-xL as a result of high Bcl-2 expression (Grillot et al., 1995) . This was elegantly confirmed in a Bcl-xL conditional knockout mouse. In this model, no alterations in cell survival and immune function were found in either effector or memory T cell (Zhang and He, 2005b) . Our results confirm the compensatory role of Bcl-2 in Bcl-xL deficient normal T cells.
In addition to Bcl-xL independence, normal peripheral T cells are insensitive to TRAIL treatment, because they do not express TRAIL receptors (Jeremias et al., 1998; Simon et al., 2001; Klose et al., 2005) . Assuming the profound role of Bcl-xL and TRAIL in BCL11B-RNAi mediated cell death, one should expect a lack of apoptosis induction in non-transformed mature T cells upon Bcl11b suppression, as demonstrated here. Notably, as Jurkat is derived from immature (Schneider et al., 1977) and huT-78 (Gootenberg et al., 1981) from fully differentiated T cells, the selective apoptogenic effect of the BCL11B suppression seems to be not only a property of the differentiation status (DN thymocytes vs mature T cells) but also of the transformed phenotype (malignant vs normal T cells).
Our study provides evidence for an antiapoptotic function of Bcl11b in T-cell malignancies. The selective Bcl11b dependence of transformed T cells makes it an attractive target for novel therapeutic strategies directed against T-ALL and T-cell lymphomas.
Materials and methods
Reagents
All biochemicals were from Sigma Chemicals (Munich, Germany) unless otherwise specified. Caspase 8 inhibitor, IETD-fluoromethyl ketone (FMK) and negative control peptide Z-FA-FMK were purchased from R&D Systems (Abingdon, UK). Caspase 9 inhibitor LEHD-FMK was provided by BD Pharmingen (Heidelberg, Germany). Human recombinant Trail was purchased from PeproTech (Peprotech Ltd, London, UK).
Antibodies
Primary antibodies for the following proteins were used: affinity-purified, anti-human Bcl11b rabbit polyclonal antibody (Biogenes, Berlin, Germany); anti-human Trail-PE mouse monoclonal antibody (R&D Systems, Abingdon, UK); anti-human Bcl-xl mouse monoclonal antibody (BD Transduction Laboratories, Erembodegem, Belgium); antiactin, affinity-purified antibody (Sigma, St Louis, MO, USA); anti-human caspase 3-FITC, active form, (BD Pharmingen). Secondary alkaline-phosphatase-conjugated donkey antimouse IgG and goat anti-rabbit antibodies were purchased from Jackson ImmunoResearch Laboratories Inc. (Soham, UK). Goat anti-mouse horseradish peroxidase (HRP) conjugated antibody was provided by Dako Cytomation (Hamburg, Germany).
Cell culture
Jurkat human T-cell leukemia (DSMZ, Braunschweig, Germany), huT78 human T-cell lymphoma cell lines (ATCC, Manassas, VA, USA) and Raji human Burkitt lymphoma cell line (ATCC) were grown in Rosewell Park Memorial Institute medium (RPMI) 1640 medium (Invitrogen, Paisley, UK), supplemented with 1 mM sodium pyruvate, 1 Â non-essential amino acids (Invitrogen), 10% fetal calf serum (FCS) (Invitrogen) and 5 mg/ml Plasmocin (Amaxa, Cologne, Germany) and maintained in a humidified incubator at 371C and 5% CO 2 . All experiments were performed using cells in exponential phase growth.
Jurkat TetR-IRES-DsRed cell line expressing the tetracycline repressor (a kind gift of DW Kowalczyk) was cultured in RPMI 1640 medium supplemented with 1 mM sodium pyruvate, 1 Â non-essential amino acids (Invitrogen), 10% TetOn System approved FCS (BD Clontech, Heidelberg, Germany).
Purified human T cells were prepared using the Pan T-Cell Isolation kit II (Miltenyi, Bergisch Gladbach, Germany) and stimulated by T-cell Activation/Expansion Kit (Miltenyi) according to the manufacturer's instructions. Cells were cultured in RPMI 1640 medium supplemented with 1 mM sodium pyruvate, 1 Â non-essential amino acids (Invitrogen), 10% FCS (PanBiotech, Aidenbach, Germany) and 20 U/ml recombinant human IL-2 (Sigma).
siRNA, plasmids and cell transfections BCL11B-specific (BCL11B-674), TRAIL-specific Stealth siRNAs and the corresponding non-silencing control (sc) RNA duplexes were designed and synthesized by Invitrogen. Prevalidated Bcl-2-specific synthetic siRNA was purchased from MWG Biotech AG (Ebersberg, Germany). Five micrograms of each siRNA were used for each transfection unless otherwise specified.
Cells were transfected with Amaxa Nucleofection Device II (Amaxa), using the Amaxa nucleofection Kit V or T-cell nucleofection kit according to the manufacturer's instructions. Other experimental conditions are given in the figure legends.
To develop the tetracycline-inducible BCL11B-specific RNA interference system, the DNA oligonucleotides were designed and purchased from Oligoengine (Seattle, WA, USA). The oligonucleotides were annealed and ligated into BglII/XhoI sites of pSuperior-Neo r -EGFP plasmid (Oligoengine) using standard cloning procedures. Plasmids were transfected into Jurkat TetR-IRES-DsRed cells using Lipofectamine2000 (Invitrogen), and stably transfected cells were selected by culturing in the presence of 1 mg/ml geneticin (Invitrogen).
The BCL-xL coding sequence was amplified and ligated into XhoI and HindIII sites of pIRES2-EGFP vector (BD Clontech, Heidelberg, Germany) using T4 DNA Ligase (Promega, Madison, WI, USA). For stable transfection, Jurkat and huT78 cells were transfected and selected in the presence of 1 mg/ml geneticin (Invitrogen)
The sequences of all siRNAs and shRNAs used in this study are provided in the Supplementary Information.
RNA isolation, expression profiling, reverse transcription and realtime QRT-PCR Total RNA was isolated from the cells with Trizol (Invitrogen). Affymetrix microarray analysis was performed using the one-cycle target Labeling and Control Reagents and Human Genome U133 Plus 2.0 DNA Microrrays (Affymetrix, Santa Clara, CA, USA) according to the manufacturer's instructions. The subsequent scanning was performed with the GeneChip Scanner 3000 (Affymetrix). The probe sets displaying signal log ratios of X1 or pÀ1 and signal differences of X200 were regarded as regulated in the knock-down sample compared to the control. For QRT-PCR, RNA was reverse transcribed with PowerScript reverse transcriptase (BD Clontech) using random hexamers (Promega).
All primers and probes were synthesized by TibMolBiol (Berlin, Germany). Quantification of BCL11B mRNA was performed as described elsewhere (Przybylski et al., 2005) . BCLxL TRAIL and b-2-microglobulin (b-2-MG) reference gene mRNA expression was measured with the 7500 RealTime PCR System (Applied Biosystems, Foster City, CA, USA) using the Platinum SYBR Green qPCR SuperMix-uracil-DNA glycosylase (Invitrogen) according to the manufacturer's instructions.
The sequences of all primers used in this study are provided in the Supplementary Information.
Apoptosis assays
Cells were treated with siRNA as described in the figure legends; 24-72 h after siRNA treatment, DNA content was analysed by propidium iodide incorporation assay. Cells were washed twice with phosphate-buffered saline (PBS), and fixed in 70% ethanol at À201C for at least 30 min. After centrifugation, cells were re-suspended in PBS containing 1% glucose, 50 mg/ml RNase A and 50 mg/ml propidium iodide (Sigma) and incubated in the dark at room temperature for 30 min. Flow cytometry analysis was performed on a Becton Dickinson (Heidelberg, Germany) FACSCalibur using CellQuest software. Apoptotic cells were detected as sub-G 0 /G 1 peak. Annexin-V-binding assays were performed at 24, 48 and 72 h after siRNA nucleofection using the BD Clontech ApoAlert Annexin-V-FITC or Annexin-V-APC (BD Pharmingen) kits according to the manufacturer's instructions. The percent apoptotic cells was quantified by FACS analysis.
Activation of caspase 3 was measured by FACS with FITClabeled active caspase 3 rabbit IgG, after fixation and permeabilization of the cells with CytoFix/CytoPerm (BD Pharmingen). Caspase 8 and 9 inhibition was achieved by IETD-FMK (R&D) and LEHD-FMK (BD Pharmingen), respectively; Z-FA-FMK peptide (R&D) was used as a negative control. Dimethylsulfoxide (DMSO) vehicle delivered at the dilutions corresponding to the concentrations of inhibitors was used as an additional control. To inhibit Trail, increasing doses (2-50 ng/ml) of Trail-neutralizing antibody (Abcam, Cambridge, UK) were added to cell cultures upon Bcl11b suppression. Caspase 3 activity was detected with Caspase-Glo 3/7 assay (Promega) and measured with a GENios luminometer (Tecan, Crailsheim, Germany).
Immunoblotting Cells were lysed on ice for 15 min (1 Â 10 7 cells/50 ml radioimmunoprecipitation assay buffer; PBS containing 1% Igepal, 0.5% deoxycholic acid and 0.1% sodium dodecyl sulfate (SDS)), supplemented with a freshly added complete protease inhibitor cocktail (Roche, Palo Alto, CA, USA) according to the supplier's instructions. After the cells had been lysed, samples were centrifuged at 10 000 g. Protein concentrations of supernatants were determined by Micro BCA assay (Pierce, Rockford, IL, USA) and samples were separated by SDS-10% polyacrylamide gel electrophoresis (PAGE) or SDS-15% PAGE (BioRad, Munich, Germany). The proteins (50 or 25 mg) were blotted onto polyvinylidine membranes (ROTH, GmbH, Karlsruhe, Germany) using a tank blotting system (BioRad). Equal protein loads were confirmed by Ponceau staining and by immunodetection of b-actin. The membranes were subsequently blocked in 50 mM Tris-buffered saline (pH ¼ 7.6) containing 3% NaCl and 3% non-fat dry milk (BioRad). Afterwards, the membranes were incubated with polyclonal rabbit anti-human Bcl11b antibodies (0.2 mg/ml, BioGenes, Berlin, Germany) and rabbit anti-actin antibodies (0.5 mg/ml, Sigma, Munich, Germany), followed by alkaline phosphatase-conjugated goat anti-rabbit antibodies (Jackson ImmunoResearch Europe Ltd). The binding was visualized by the Sigma Fast BCIP/NBT buffered substrate. Bcl-xL protein was detected using anti-human Bcl-xL mouse antibodies (0.5 mg/ml, BD Transduction Laboratories, Erembodegem, Belgium) followed by goat anti-mouse IgG-HRP (Dako Cytomation GmbH, Hamburg, Germany) and visualized by enhanced chemiluminescence Plus detection reagents (Amersham Biosciences, Uppsala, Sweden) using Image Station 440CF (Kodak, Rochester, NY, USA).
ELISA assay
Intracellular human Trail levels were measured with Human TRAIL/TNFSF10 Quantikine ELISA Kit (R&D Systems) in Jurkat, huT78 and normal T cells subjected to BCL11B siRNA-mediated suppression. Cells were counted and 1 Â 10 6 of cells were lysed and measured 48 h after transfection according to the manufacturer's instructions.
Cytofluorometric analysis
Cells were prepared for FACS measurements according to the protocols provided with the assays or antibodies and measured with FACSCalibur (Becton Dickinson). The results were analysed using CellQuest and WinMDI 2.8 software.
Statistical analysis
All experiments were performed at least in triplicate. Statistical significance of the observed differences was analysed by Statistica Software (StatSoft Inc., Tulsa, OK, USA), using the Student's t-test for unpaired (for Jurkat and huT78 cells) or Student's t-test for paired data (normal T cells from healthy individuals).
